Skip to content
Study details
Enrolling now

Dose Range Finding Trial for Tozorakimab in Adults With Uncontrolled Asthma

AstraZeneca
NCT IDNCT06932263ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

540

Study length

about 3 years

Ages

18–75

Locations

51 sites in CA, DE, FL +22

What this study is about

This trial is testing different doses of tozorakimab, a medication given by injection, in adults with uncontrolled asthma who are already taking medium-to-high doses of inhaled corticosteroids. The goal is to see if these doses are effective and safe.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take Tozorakimab

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

monoclonal antibody

Endpoints

Secondary: Change from baseline in post-bronchodilator FEV1, Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1), Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6), Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ12+)

Body systems

Respiratory